Stemetix, Inc. is a Needham, Massachusetts biotechnology company focused on small-molecule drug development for neurological recovery following stroke and traumatic brain injury. The company discovered novel small molecules that bind to the FGF-2/receptor (FGFR1) complex and enhance FGF-2 signal transduction, promoting neurological recovery after ischemic stroke. Stemetix was founded by Seth Finklestein (CEO) and Ray Soumya, with scientific roots in research at Harvard/Massachusetts General Hospital. The company received HHS SBIR funding including a $1.35M grant in 2018. According to secondary sources, Stemetix is currently inactive (deadpooled).
Create a free account to see funding visualizations and detailed round data.
Create Free AccountNo funding data available yet.
Know something? Help us improve our data.
Create a free account to see which investors have funded this company.
Create Free Account
